SUNA and the AUA have collaborated to develop a Standard Operating Procedure (SOP) for instillation of intravesical cytotoxic, immunotherapeutic, and/or therapeutic drugs for patients with urothelial carcinoma of the bladder and interstitial cystitis. This lecture is an overview of the SOP to include indications for administration, guidelines and principles of hazardous drugs in the clinical setting, peri-treatment concerns, as well as patient and staff education.

Contact hours available until 10/26/17.

Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNE evaluation. You will be able to print your CNE certificate at any time after you complete the evaluation.

Planning Committee Disclosures:
• Gina Powley - Astellas/Medivation speaker bureau, Ferring Pharmaceuticals speaker bureau
• Leanne Schimke, MSN, CRNP, CUNP - Consultant: Bayer, Speaker's Bureau: Bayer
• Valre Welch, MSN, CPNP - Holister Continence Care Advisory Board; Speaker for Hollister Incontinence Workshops

Speaker Disclosures:
There are no disclosures to declare.

Commercial Support and Sponsorship:
No commercial support or sponsorship declared.

Accreditation Statement:
Society of Urologic Nurses and Associates is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

SUNA is a provider approved by the California Board of Registered Nursing, provider number, CEP 5556.

Objectives:
1. Outline an overview of the SUNA/AUA Intravesical Administration of Therapeutic Medication Standard Operating Procedure.
2. Recognize healthcare personnel risks of potential hazardous drug exposures and how to reduce exposure.
3. Utilize the 2004 NIOSH Alert to improve safe clinical practices.

Debbie Hensley BSN, RN, CURN

UT Southwestern Medical Center

Appearances